By replacing a single hydrogen atom with deuterium in a 3-year-old cystic fibrosis drug developed by Vertex Pharmaceuticals, Lexington-based Concert Pharmaceuticals says it was able to show the altered version works better in a small, early-stage clinical trial.http://www.bizjournals.com/boston/blog/bioflash/2015/09/concert-shares-soar-as-it-bests-vertex-cystic.html?ana=Yahoo
No comments:
Post a Comment